Condition: Advanced Solid Tumors With KRAS G12C Mutations · Solid Tumor, Adult · Unresectable Solid Tumor · Sponsor: Frontier Medicines Corporation
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
This description comes directly from the study's public registry record.
Medical Lead · +1 (650) 457-1005 · clinicaltrials@frontiermeds.com
Always discuss trial participation with your own doctor first.
| University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center | La Jolla, California, United States | Recruiting |
| University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center | Orange, California, United States | Completed |
| University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Florida Cancer Specialists and Research Institute | Lake Mary, Florida, United States | Completed |
| Northwest Cancer Centers | Dyer, Indiana, United States | Recruiting |
| The University of Kansas Cancer Center | Fairway, Kansas, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Community Clinical Trials | Kingwood, Texas, United States | Completed |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio, Texas, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06244771